Opin vísindi

Re-evaluation of neohesperidine dihydrochalcone (E 959) as a food additive

Skoða venjulega færslu

dc.contributor.author EFSA Panel on Food Additives and Flavourings (FAF)
dc.date.accessioned 2023-08-15T01:05:59Z
dc.date.available 2023-08-15T01:05:59Z
dc.date.issued 2022-11
dc.identifier.citation EFSA Panel on Food Additives and Flavourings (FAF) 2022 , ' Re-evaluation of neohesperidine dihydrochalcone (E 959) as a food additive ' , EFSA Journal , vol. 20 , no. 11 , e07595 . https://doi.org/10.2903/j.efsa.2022.7595
dc.identifier.issn 1831-4732
dc.identifier.other 86822460
dc.identifier.other 7e502ce1-c37d-49f3-b713-8327545b6421
dc.identifier.other 85146562740
dc.identifier.uri https://hdl.handle.net/20.500.11815/4404
dc.description Publisher Copyright: © 2022 Wiley-VCH Verlag GmbH & Co. KgaA on behalf of the European Food Safety Authority.
dc.description.abstract The present opinion deals with the re-evaluation of neohesperidine dihydrochalcone (E 959) when used as a food additive. It is obtained by catalytic hydrogenation of a flavanone – neohesperidine – which is naturally occurring and thus isolated by alcohol extraction in bitter oranges (Citrus aurantium). Based on in vivo data in rat, neohesperidine dihydrochalcone is likely to be absorbed, also in humans, and to become systemically available. It does not raise a concern regarding genotoxicity. The toxicity data set consisted of studies on subchronic and prenatal developmental toxicity. No human studies were available. The data set was considered sufficient to derive a new acceptable daily intake (ADI). Based on the weight of evidence (WoE) analysis, the Panel considered unlikely that neohesperidine dihydrochalcone would lead to adverse effects on health in animals in the dose ranges tested. The Panel also considered that a carcinogenicity study was not warranted and that the lack of human data did not affect the overall confidence in the body of evidence. The Panel derived an ADI of 20 mg/kg bodyweight (bw) per day based on a no observed adverse effect level (NOAEL) of 4,000 mg/kg bw per day from a 13-week study in rat, applying the standard default factors of 100 for inter- and intraspecies differences and of 2 for extrapolation from subchronic to chronic exposure. For the refined brand-loyal exposure assessment scenario, considered to be the most appropriate for the risk assessment, the exposure estimates at the mean ranged from < 0.01 to 0.09 mg/kg bw per day and at the 95th percentile (P95) from 0.01 to 0.24 mg/kg bw per day. Considering the derived ADI of 20 mg/kg bw per day, the exposure estimates were below the reference value in all age groups. Therefore, the Panel concluded that dietary exposure to the food additive neohesperidine dihydrochalcone (E 959) at the reported uses and use levels would not raise a safety concern.
dc.format.extent 9990701
dc.format.extent
dc.language.iso en
dc.relation.ispartofseries EFSA Journal; 20(11)
dc.rights info:eu-repo/semantics/openAccess
dc.subject E 959
dc.subject food additive
dc.subject neohesperidine dihydrochalcone
dc.subject sweetener
dc.subject Parasitology
dc.subject Food Science
dc.subject Microbiology
dc.subject Animal Science and Zoology
dc.subject Veterinary (miscellaneous)
dc.subject Plant Science
dc.title Re-evaluation of neohesperidine dihydrochalcone (E 959) as a food additive
dc.type /dk/atira/pure/researchoutput/researchoutputtypes/contributiontojournal/article
dc.description.version Peer reviewed
dc.identifier.doi 10.2903/j.efsa.2022.7595
dc.relation.url http://www.scopus.com/inward/record.url?scp=85146562740&partnerID=8YFLogxK
dc.contributor.department Faculty of Food Science and Nutrition


Skrár

Þetta verk birtist í eftirfarandi safni/söfnum:

Skoða venjulega færslu